3,623
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease

, , , , , , , , & show all
Pages 233-242 | Received 03 Aug 2016, Accepted 03 Oct 2016, Published online: 03 Feb 2017

References

  • Abraham C, Cho JH. (2009). Inflammatory bowel disease. N Engl J Med 361:2066–78
  • Beloqui A, Coco R, Alhouayek M, et al. (2013). Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm 454:775–83
  • Dandekar PP, Jain R, Patil S, et al. (2010). Curcumin-loaded hydrogel nanoparticles: application in anti-malarial therapy and toxicological evaluation. J Pharm Sci 99:4992–5010
  • Dulbecco P, Savarino V. (2013). Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol 19:9256–70
  • Hua S, Marks E, Schneider JJ, Keely S. (2015). Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 11:1117–32
  • Khor B, Gardet A, Xavier RJ. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature 474:307–17
  • Lahiff C, Moss AC. (2011). Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis 17:E66
  • Lamprecht A, Schafer U, Lehr CM. (2001). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788–93
  • Lautenschlager C, Schmidt C, Lehr CM, et al. (2013). PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm 85:578–86
  • Li J, Huo M, Wang J, et al. (2012). Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials 33:2310–20
  • Li Q, Zhai W, Jiang Q, et al. (2015). Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharm 490:22–31
  • Magro F, Langner C, Driessen A, et al. (2013). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 7:827–51
  • Nielsen OH, Ainsworth MA. (2013). Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 369:754–62
  • Qiao H, Sun M, Su Z, et al. (2014). Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan. Biomaterials 35:7157–71
  • Saphier S, Haft A, Margel S. (2012). Bacterial reduction as means for colonic drug delivery: can other chemical groups provide an alternative to the azo bond? J Med Chem 55:10781–5
  • Sinha VR, Kumria R. (2003). Microbially triggered drug delivery to the colon. Eur J Pharm Sci 18:3–18
  • Sreedhar R, Arumugam S, Thandavarayan RA, et al. (2016). Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Drug Discov Today 21:843–9
  • Tang H, Murphy CJ, Zhang B, et al. (2010). Curcumin polymers as anticancer conjugates. Biomaterials 31:7139–49
  • Wilson DS, Dalmasso G, Wang L, et al. (2010). Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9:923–8
  • Yin S, Huai J, Chen X, et al. (2015). Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid. Acta Biomater 26:274–85
  • Youshia J, Lamprecht A. (2016). Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Expert Opin Drug Deliv 13:281–94
  • Zhongfa L, Chiu M, Wang J, et al. (2012). Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69:679–89